Peroxisome proliferator-activated receptor γ-independent effects of thiazolidinediones on human cardiac myofibroblast function

Romana S. Mughal, Philip Warburton, David J. O'Regan, Stephen G. Ball, Neil A. Turner, Karen E. Porter

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR) γ agonists that are used to lower insulin resistance in Type 2 diabetic patients. Although TZDs exhibit beneficial effects on the vasculature, their effects on the heart are less clear and are the subject of current clinical debate. Thiazolidinediones have been reported to reduce adverse myocardial remodelling, a pathology in which cardiac myofibroblasts (CMF) are pivotal. The aim of the present study was to investigate whether TZDs modulate specific human CMF functions of importance to the myocardial remodelling process and to determine whether any of these effects were mediated via PPARγ activation. Immunoblotting of cultured human CMF homogenates revealed strong expression of PPARγ (approximately 50 kDa). Three different TZDs (ciglitazone, rosiglitazone and troglitazone) and the endogenous PPARγ ligand 15-deoxy-δ12,14-prostaglandin J2 (15d-PGJ2) inhibited CMF proliferation (cell number and expression of proliferating cell nuclear antigen) in a concentration-dependent manner (range 0.1-10 mol/L) with similar potencies. This antiproliferative effect of TZDs was not reversed by the PPARγ antagonists GW9662 or T0070907 (10-25 mol/L). None of the TZDs or 15d-PGJ2 affected cell migration or invasion (Boyden chamber assays without or with Matrigel barrier), matrix metalloproteinase-2 or -9 secretion (gelatin zymography) or the actin cytoskeleton (rhodamine/phalloidin fluorescent confocal microscopy). In conclusion, TZDs reduce human CMF proliferation via a PPARγ-independent mechanism. Although TZDs do not inhibit CMF invasion, their antiproliferative activity may contribute to the ability of this class of drugs to modulate adverse myocardial remodelling.

LanguageEnglish
Pages478-486
Number of pages9
JournalClinical and Experimental Pharmacology and Physiology
Volume36
Issue number5-6
DOIs
Publication statusPublished - 1 May 2009
Externally publishedYes

Fingerprint

Thiazolidinediones
Myofibroblasts
PPAR gamma
rosiglitazone
troglitazone
Matrix Metalloproteinase 2
Proliferating Cell Nuclear Antigen
Gelatin
Actin Cytoskeleton
Immunoblotting
Confocal Microscopy
Cell Movement
Insulin Resistance
Cell Count
Pathology
Ligands

Cite this

Mughal, Romana S. ; Warburton, Philip ; O'Regan, David J. ; Ball, Stephen G. ; Turner, Neil A. ; Porter, Karen E. / Peroxisome proliferator-activated receptor γ-independent effects of thiazolidinediones on human cardiac myofibroblast function. In: Clinical and Experimental Pharmacology and Physiology. 2009 ; Vol. 36, No. 5-6. pp. 478-486.
@article{18e60c7cd19247a68fdec2b87fe07a2d,
title = "Peroxisome proliferator-activated receptor γ-independent effects of thiazolidinediones on human cardiac myofibroblast function",
abstract = "Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR) γ agonists that are used to lower insulin resistance in Type 2 diabetic patients. Although TZDs exhibit beneficial effects on the vasculature, their effects on the heart are less clear and are the subject of current clinical debate. Thiazolidinediones have been reported to reduce adverse myocardial remodelling, a pathology in which cardiac myofibroblasts (CMF) are pivotal. The aim of the present study was to investigate whether TZDs modulate specific human CMF functions of importance to the myocardial remodelling process and to determine whether any of these effects were mediated via PPARγ activation. Immunoblotting of cultured human CMF homogenates revealed strong expression of PPARγ (approximately 50 kDa). Three different TZDs (ciglitazone, rosiglitazone and troglitazone) and the endogenous PPARγ ligand 15-deoxy-δ12,14-prostaglandin J2 (15d-PGJ2) inhibited CMF proliferation (cell number and expression of proliferating cell nuclear antigen) in a concentration-dependent manner (range 0.1-10 mol/L) with similar potencies. This antiproliferative effect of TZDs was not reversed by the PPARγ antagonists GW9662 or T0070907 (10-25 mol/L). None of the TZDs or 15d-PGJ2 affected cell migration or invasion (Boyden chamber assays without or with Matrigel barrier), matrix metalloproteinase-2 or -9 secretion (gelatin zymography) or the actin cytoskeleton (rhodamine/phalloidin fluorescent confocal microscopy). In conclusion, TZDs reduce human CMF proliferation via a PPARγ-independent mechanism. Although TZDs do not inhibit CMF invasion, their antiproliferative activity may contribute to the ability of this class of drugs to modulate adverse myocardial remodelling.",
keywords = "Cardiac myofibroblast, Matrix metalloproteinase, Migration, Peroxisome proliferator-activated receptor γ, Proliferation, Thiazolidinediones",
author = "Mughal, {Romana S.} and Philip Warburton and O'Regan, {David J.} and Ball, {Stephen G.} and Turner, {Neil A.} and Porter, {Karen E.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1111/j.1440-1681.2008.05088.x",
language = "English",
volume = "36",
pages = "478--486",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "5-6",

}

Peroxisome proliferator-activated receptor γ-independent effects of thiazolidinediones on human cardiac myofibroblast function. / Mughal, Romana S.; Warburton, Philip; O'Regan, David J.; Ball, Stephen G.; Turner, Neil A.; Porter, Karen E.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 36, No. 5-6, 01.05.2009, p. 478-486.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peroxisome proliferator-activated receptor γ-independent effects of thiazolidinediones on human cardiac myofibroblast function

AU - Mughal, Romana S.

AU - Warburton, Philip

AU - O'Regan, David J.

AU - Ball, Stephen G.

AU - Turner, Neil A.

AU - Porter, Karen E.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR) γ agonists that are used to lower insulin resistance in Type 2 diabetic patients. Although TZDs exhibit beneficial effects on the vasculature, their effects on the heart are less clear and are the subject of current clinical debate. Thiazolidinediones have been reported to reduce adverse myocardial remodelling, a pathology in which cardiac myofibroblasts (CMF) are pivotal. The aim of the present study was to investigate whether TZDs modulate specific human CMF functions of importance to the myocardial remodelling process and to determine whether any of these effects were mediated via PPARγ activation. Immunoblotting of cultured human CMF homogenates revealed strong expression of PPARγ (approximately 50 kDa). Three different TZDs (ciglitazone, rosiglitazone and troglitazone) and the endogenous PPARγ ligand 15-deoxy-δ12,14-prostaglandin J2 (15d-PGJ2) inhibited CMF proliferation (cell number and expression of proliferating cell nuclear antigen) in a concentration-dependent manner (range 0.1-10 mol/L) with similar potencies. This antiproliferative effect of TZDs was not reversed by the PPARγ antagonists GW9662 or T0070907 (10-25 mol/L). None of the TZDs or 15d-PGJ2 affected cell migration or invasion (Boyden chamber assays without or with Matrigel barrier), matrix metalloproteinase-2 or -9 secretion (gelatin zymography) or the actin cytoskeleton (rhodamine/phalloidin fluorescent confocal microscopy). In conclusion, TZDs reduce human CMF proliferation via a PPARγ-independent mechanism. Although TZDs do not inhibit CMF invasion, their antiproliferative activity may contribute to the ability of this class of drugs to modulate adverse myocardial remodelling.

AB - Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR) γ agonists that are used to lower insulin resistance in Type 2 diabetic patients. Although TZDs exhibit beneficial effects on the vasculature, their effects on the heart are less clear and are the subject of current clinical debate. Thiazolidinediones have been reported to reduce adverse myocardial remodelling, a pathology in which cardiac myofibroblasts (CMF) are pivotal. The aim of the present study was to investigate whether TZDs modulate specific human CMF functions of importance to the myocardial remodelling process and to determine whether any of these effects were mediated via PPARγ activation. Immunoblotting of cultured human CMF homogenates revealed strong expression of PPARγ (approximately 50 kDa). Three different TZDs (ciglitazone, rosiglitazone and troglitazone) and the endogenous PPARγ ligand 15-deoxy-δ12,14-prostaglandin J2 (15d-PGJ2) inhibited CMF proliferation (cell number and expression of proliferating cell nuclear antigen) in a concentration-dependent manner (range 0.1-10 mol/L) with similar potencies. This antiproliferative effect of TZDs was not reversed by the PPARγ antagonists GW9662 or T0070907 (10-25 mol/L). None of the TZDs or 15d-PGJ2 affected cell migration or invasion (Boyden chamber assays without or with Matrigel barrier), matrix metalloproteinase-2 or -9 secretion (gelatin zymography) or the actin cytoskeleton (rhodamine/phalloidin fluorescent confocal microscopy). In conclusion, TZDs reduce human CMF proliferation via a PPARγ-independent mechanism. Although TZDs do not inhibit CMF invasion, their antiproliferative activity may contribute to the ability of this class of drugs to modulate adverse myocardial remodelling.

KW - Cardiac myofibroblast

KW - Matrix metalloproteinase

KW - Migration

KW - Peroxisome proliferator-activated receptor γ

KW - Proliferation

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=65349122338&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1681.2008.05088.x

DO - 10.1111/j.1440-1681.2008.05088.x

M3 - Article

VL - 36

SP - 478

EP - 486

JO - Clinical and Experimental Pharmacology and Physiology

T2 - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 5-6

ER -